Home Biosimilar Antibodies Angiogenesis EGFR inhibitor Cetuximab (anti-EGFR)
For research use only. Not for use in humans.

Cetuximab (anti-EGFR)

Synonyms: C225

Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW：145.781 KD.

Cetuximab (anti-EGFR) Chemical Structure

Click to purchase the isotype control of Cetuximab (anti-EGFR)

58 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99.81% Protein concentration: 3.63 mg/ml Endotoxin Level: <1 EU/mg
99.81

Specificity

Name Citation EGFR/ErbB1 HER2/ErbB2 ErbB3 ErbB4 mutant EGFR Others
Saracatinib (AZD0530) 307 c-Src,c-YES,LCK
Canertinib (CI-1033) 48
AG-490 132 JAK2 (V617F)
CP-724714 109
WZ4002 34
Sapitinib (AZD8931) 50
CUDC-101 23 HDAC,HDAC1,HDAC6
AG-1478 99
PD153035 HCl 17
Pelitinib (EKB-569) 11 Src,MEK/ERK,Raf
AEE788 (NVP-AEE788) 13 c-Abl,FLT1,c-Fms
AC480 (BMS-599626) 10
AP26113-analog (ALK-IN-1) 4 ALK,IGF1R,INSR
WZ3146 2
Allitinib tosylate 18
Rociletinib (CO-1686) 37
Varlitinib 8
Icotinib (BPI-2009H) 10
TAK-285 4 MEK1,Aurora B,LCK
WHI-P154 11 Src,VEGFR,JAK3
Daphnetin 4 PKA,PKC
PD168393 6
CNX-2006 2
Tyrphostin 9 1 PDGFR
AG-18 1
Icotinib Hydrochloride 0
HS-10296 hydrochloride 0
MTX-531 0 PI3Kα
Avitinib maleate 0 BTK
limertinib 0
AG 825 0 PDGFR
4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine 0
AST-1306 2
ErbB2 inhibitor 0
Tuxobertinib (BDTX-189) 2 RIPK2,BLK
Epertinib hydrochloride 0
JND3229 0 EGFR C797S
BI-4020 1
Tyrphostin AG-528 0
AG 556 0
Canertinib dihydrochloride 8
EGFR Inhibitor 3 Microtubules
SU5214 0 VEGFR2
RG 13022 0
TQB3804 1
zipalertinib (TAS6417) 3 TXK,BMX
Pyrotinib dimaleate 4
PD153035 14
AG 494 0
AG 555 0
Theliatinib (HMPL-309) 0
Avitinib (Abivertinib) 3 JAK3,BTK
Lazertinib (YH25448) 9 Del19,L85R
Lifirafenib (BGB-283) 6 WT A-RAF,C-RAF (Y340/341D),BRAF(V600E)
Nazartinib (EGF816) 6
Zorifertinib (AZD3759) 6
CL-387785 (EKI-785) 5
Poziotinib (HM781-36B) 35
AZ5104 4 ACK1,BLK,BRK
AV-412 free base 0
HER2-Inhibitor-1 1
WZ8040 3
Genistein 35 topo II
Rezivertinib 1
BDTX-1535 0
Falnidamol 0
BLU-945 1
(S)-Sunvozertinib ((S)-DZD9008) 1
CH7233163 1
Licochalcone D 0 NF-κB,PARP,Caspase
Alflutinib (Furmonertinib) mesylate 3 CYP3A4
(Rac)-JBJ-04-125-02 0
Tyrphostin AG30 (AG30) 0
AG-1557 0
AG99 0
MTX-211 2 PI3K
RG14620 0 ABCG2
Almonertinib (HS-10296) 4
Cyasterone 1
Norcantharidin 3 c-Met
Naquotinib(ASP8273) 1
EAI045 2
Olmutinib (BI 1482694) 6 BTK
Butein 2
Chrysophanic Acid 3 mTOR
EGCG ((-)-Epigallocatechin Gallate) 42 DNMT,telomerase,FASN
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW：145.781 KD.
Features
Human IgG1
In vitro

Cetuximab treatment increases mitochondrial priming of EGFR-expressing HeLa cells but not in EGFR-expressing MDA-MD-231 cells.
Cell Research

Cells were lysed at a density of 1 x 106/50 μL in lysis buffer (0.25 M Tris-HCl, 2% sodium dodecylsulfate, 4% β-mercaptoethanol, 10% glycerol, 0.02% bromophenol blue) supplemented with 1 X protease/phosphatase inhibitor cocktail. Cell lysates were then loaded onto polyacrylamide gels with sodium dodecyl sulfate. After electrophoresis, proteins were transferred to polyvinylidene difluoride (PVDF) membranes. The transblotted membranes were blocked for 1 hr and then probed with appropriate primary antibodies overnight at 4 ℃. Next day, the membranes were washed three times for a total of 30 min and then incubated with IRDye 680RD Donkey anti-Rabbit IgG (H + L) or IRDye 800CW Donkey anti-Mouse IgG (H + L) in darkness at room temperature for 1 h. After another three washes, scan immunoblot membranes and quantify band intensity.
In vivo

C225 enhanced the antitumor activity of several chemotherapeutic drugs in mouse xenograft models. Cetuximab, exerts its antitumor efficacy by multiple mechanisms that include the inhibition of cell cycle progression by arrest in the G1- phase and decreased cell number in the S-phase. Cell cycle arrest in the G1-phase also induces apoptosis by the induction and activation of proapoptotic molecules. cetuximab alone and in synergy with carboplatin resulted in decreases of tumor size, metastatic spread, and MVD in NCI-N87 tumors with EGFR cell surface expression and absence of mutations in BRAF and K-ras, whereas cetuximab had minimal in vitro effect and no in vivo treatment efficacy in tumors derived from MKN-45, in which the phenotype was also BRAF and K-ras wildtype, but which had only weak cytoplasmic EGFR protein expression.
Animal Research

Objective: Antitumor activity of cetuximab in murine gastric cancer model
Animal Models: Nude mouse model for human gastric cancer (CD-1/nu-nu mice)
Formulation: 0.9% NaCl
Dosages: 1 mg/kg
Administration: i.p.
Reference: https://www.ncbi.nlm.nih.gov/pubmed/22011788

Objective: To investigate the relationship between the EGFR levels and the responsiveness to cetuximab treatment in human cancer xenograft models
Animal Models: Female athymic, nude mice were implanted s.c. with ~1 mm3 tumor fragments
Formulation: PBS
Dosages: 0.25, 0.5 or 1 mg/mouse
Administration: i.p.
Reference: https://www.ncbi.nlm.nih.gov/pubmed/27186886

Cetuximab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)
References

Product Details

CAS No. 205923-56-4
Isotype Human IgG1
Source CHO cells
Formulation 100 mM Pro-Ac, 20 mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.